Teplizumab-induced partial exhaustion of CD8+ T memory cells (KLRG1+TIGIT+) has been associated with a positive clinical response to teplizumab in stage 2 type 1 diabetes [24, 25]. This evidence concerns the gene KLRG1 and type 1 diabetes mellitus.